<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801992</url>
  </required_header>
  <id_info>
    <org_study_id>PSM8 Sub-study</org_study_id>
    <nct_id>NCT04801992</nct_id>
  </id_info>
  <brief_title>Trial Following Subjects Bilaterally Implanted With Mini Well Ready For 2 Years After the Second Eye Implant</brief_title>
  <official_title>Retrospective, Observational, Monocenter And Single-Arm Trial Following Subjects Bilaterally Implanted With Mini Well Ready For 2 Years After The Second Eye Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIFI SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera CRO, a TIGERMED Group Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SIFI SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the visual performance of MINI WELL Ready at 24 months&#xD;
      following the second eye implant. The objectives of safety are to evaluate the rate of&#xD;
      Secondary Surgical Interventions related to the optical properties of the IOL for first and&#xD;
      second operative eye separately at 24 months and the rate of visual disturbances and&#xD;
      distortions as reported by the subjects as detected by using the Halo &amp; Glare Simulator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present post-.market follow-up study (PSM8 sub-study) is an ancillary study of the PSM8&#xD;
      post market clinical trial (NCT02740010)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Refraction</measure>
    <time_frame>26 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular Defocus Curve</measure>
    <time_frame>26 months</time_frame>
    <description>Binocular Defocus Curve (+2.0 D to -4.0 D in 0.5 D increments)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UDVA</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Uncorrected Distance Visual Acuity (UDVA) at 4m</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CDVA</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Corrected Distance Visual Acuity (CDVA) at 4m</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UIVA at 100 cm</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Uncorrected Intermediate Visual Acuity at 100 cm (100% and 10% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCIVA at 100 cm</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Distance Corrected Intermediate Visual at 100 cm (100% and 10% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UIVA at 60 cm</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Uncorrected Intermediate Visual Acuity at 60 cm (100% and 10% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCIVA at 60 cm</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Distance Corrected Intermediate Visual Acuity at 60 cm (100% and 10% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UNVA</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Uncorrected Near Visual Acuity at 40cm (100% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCNVA</measure>
    <time_frame>26 months</time_frame>
    <description>Monocular and Binocular Distance Corrected Near Visual Acuity at 40cm (100% contrast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>26 months</time_frame>
    <description>Binocular Contrast Sensitivity with correction for distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reading Performance</measure>
    <time_frame>26 months</time_frame>
    <description>Binocular Reading Performance with and without correction for distance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VR-11R</measure>
    <time_frame>26 months</time_frame>
    <description>Visual Function -11R Questionnaire from 4 (without difficulties) to 0 (performance impossible due to difficulties)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications Rate of postoperative complication</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Posterior Capsule Opacification</measure>
    <time_frame>20-26 months</time_frame>
    <description>Subjective assessment through slit lamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posterior Capsulotomy</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events including SSIs</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Deficiencies</measure>
    <time_frame>26 months</time_frame>
    <description>Descriptive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photic Phenomena Assessment</measure>
    <time_frame>26 months</time_frame>
    <description>Using the Halo and Glare Simulator software</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>MINI WELL Ready (SIFI SpA, Italy)</arm_group_label>
    <description>Extended depth of focus intraocular lens implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINI WELL Ready (SIFI SpA, Italy)</intervention_name>
    <description>Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.</description>
    <arm_group_label>MINI WELL Ready (SIFI SpA, Italy)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects affected by cataract that fulfill eligibility criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Previous enrolment in the PSM8 study in the period from March, 1st 2014 to March, 31st&#xD;
        2016 with the following:&#xD;
&#xD;
          -  Any gender and age above 18 years.&#xD;
&#xD;
          -  Cataract or Refractive Lens Exchange (RLE) surgery; will be included patients&#xD;
             submitted to conventional phacoemulsification as to femtolaser procedure; no&#xD;
             specification regarding corneal incision size and position.&#xD;
&#xD;
          -  Symmetrical preoperative keratometric astigmatism &lt; 1.00 D.&#xD;
&#xD;
          -  Healthy corneas, not surgically treated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous corneal surgery (i.e. pterygium, refractive surgery).&#xD;
&#xD;
          -  Eye diseases with visual acuity &lt; 20/32.&#xD;
&#xD;
          -  Pseudoexfoliation.&#xD;
&#xD;
          -  Abnormal pupil size and position.&#xD;
&#xD;
          -  Use of contact lens 30 days before the preoperative visit.&#xD;
&#xD;
          -  Corneal warpage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>U.O. Oftalmologia I Dipartimento di Scienze Mediche di Base, Neuroscienze e Organi di Senso Università degli Studi di Bari &quot;Aldo Moro&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Jiang T, Jiang J, Zhou Y, Zhao GQ, Li H, Zhao SY. Cataract surgery in aged patients: phacoemulsification or small-incision extracapsular cataract surgery. Int J Ophthalmol. 2011;4(5):513-8. doi: 10.3980/j.issn.2222-3959.2011.05.11. Epub 2011 Oct 18.</citation>
    <PMID>22553713</PMID>
  </results_reference>
  <results_reference>
    <citation>Packer M, Fine IH, Hoffman RS. Aspheric intraocular lens selection: the evolution of refractive cataract surgery. Curr Opin Ophthalmol. 2008 Jan;19(1):1-4.</citation>
    <PMID>18090888</PMID>
  </results_reference>
  <results_reference>
    <citation>Kohnen T, Klaproth OK, Bühren J. Effect of intraocular lens asphericity on quality of vision after cataract removal: an intraindividual comparison. Ophthalmology. 2009 Sep;116(9):1697-706. doi: 10.1016/j.ophtha.2009.03.052. Epub 2009 Jul 29.</citation>
    <PMID>19643497</PMID>
  </results_reference>
  <results_reference>
    <citation>Becker KA, Martin M, Rabsilber TM, Entz BB, Reuland AJ, Auffarth GU. Prospective, non-randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study. Br J Ophthalmol. 2006 Aug;90(8):971-4. Epub 2006 May 10.</citation>
    <PMID>16687454</PMID>
  </results_reference>
  <results_reference>
    <citation>Lehmann R, Waycaster C, Hileman K. A comparison of patient-reported outcomes from an apodized diffractive intraocular lens and a conventional monofocal intraocular lens. Curr Med Res Opin. 2006 Dec;22(12):2591-602.</citation>
    <PMID>17166341</PMID>
  </results_reference>
  <results_reference>
    <citation>Leyland M, Zinicola E. Multifocal versus monofocal intraocular lenses in cataract surgery: a systematic review. Ophthalmology. 2003 Sep;110(9):1789-98. Review.</citation>
    <PMID>13129879</PMID>
  </results_reference>
  <results_reference>
    <citation>Steinert RF. Visual outcomes with multifocal intraocular lenses. Curr Opin Ophthalmol. 2000 Feb;11(1):12-21. Review.</citation>
    <PMID>10724823</PMID>
  </results_reference>
  <results_reference>
    <citation>Blaylock JF, Si Z, Vickers C. Visual and refractive status at different focal distances after implantation of the ReSTOR multifocal intraocular lens. J Cataract Refract Surg. 2006 Sep;32(9):1464-73.</citation>
    <PMID>16931257</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract surgery</keyword>
  <keyword>Extended Depth-of-Focus (EDOF)</keyword>
  <keyword>Intraocular Lens (IOL)</keyword>
  <keyword>Presbyiopa correction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

